LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia

The expression levels of LPL, ZAP70, TCL1A, CLLU1 and MCL1 have recently been proposed as prognostic factors in chronic lymphocytic leukemia. However, few studies have systematically compared these different RNA-based markers. Design and Methods Using real-time quantitative PCR, we measured the...

Full description

Bibliographic Details
Main Author:	Bin Kaderi, Mohd Arifin
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2011
Subjects:	RB Pathology RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Online Access:	http://irep.iium.edu.my/4365/ http://irep.iium.edu.my/4365/ http://irep.iium.edu.my/4365/ http://irep.iium.edu.my/4365/1/RNA_marker_paper.pdf

id	iium-4365
recordtype	eprints
spelling	iium-43652011-11-24T03:58:25Z http://irep.iium.edu.my/4365/ LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia Bin Kaderi, Mohd Arifin RB Pathology RC0254 Neoplasms. Tumors. Oncology (including Cancer) The expression levels of LPL, ZAP70, TCL1A, CLLU1 and MCL1 have recently been proposed as prognostic factors in chronic lymphocytic leukemia. However, few studies have systematically compared these different RNA-based markers. Design and Methods Using real-time quantitative PCR, we measured the mRNA expression levels of these genes in unsorted samples from 252 newly diagnosed chronic lymphocytic leukemia patients and correlated our data with established prognostic markers (for example Binet stage, CD38, IGHV gene mutational status and genomic aberrations) and clinical outcome. Results High expression levels of all RNA-based markers, except MCL1, predicted shorter overall survival and time to treatment, with LPL being the most significant. In multivariate analysis including the RNA-based markers, LPL expression was the only independent prognostic marker for overall survival and time to treatment. When studying LPL expression and the established markers, LPL expression retained its independent prognostic strength for overall survival. All of the RNA-based markers, albeit with varying ability, added prognostic information to established markers, with LPL expression giving the most significant results. Notably, high LPL expression predicted a worse outcome in good-prognosis subgroups, such as patients with mutated IGHV genes, Binet stage A, CD38 negativity or favorable cytogenetics. In particular, the combination of LPL expression and CD38 could further stratify Binet stage A patients. Conclusions LPL expression is the strongest RNA-based prognostic marker in chronic lymphocytic leukemia that could potentially be applied to predict outcome in the clinical setting, particularly in the large group of patients with favorable prognosis. Ferrata Storti Foundation 2011-08 Article PeerReviewed application/pdf en http://irep.iium.edu.my/4365/1/RNA_marker_paper.pdf Bin Kaderi, Mohd Arifin (2011) LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. Haematologica, 96 (8). pp. 1153-1160. ISSN 1592-8721 (In Press) http://www.haematologica.org/ doi:10.3324/haematol.2010.039396
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English
topic	RB Pathology RC0254 Neoplasms. Tumors. Oncology (including Cancer)
spellingShingle	RB Pathology RC0254 Neoplasms. Tumors. Oncology (including Cancer) Bin Kaderi, Mohd Arifin LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
description	The expression levels of LPL, ZAP70, TCL1A, CLLU1 and MCL1 have recently been proposed as prognostic factors in chronic lymphocytic leukemia. However, few studies have systematically compared these different RNA-based markers. Design and Methods Using real-time quantitative PCR, we measured the mRNA expression levels of these genes in unsorted samples from 252 newly diagnosed chronic lymphocytic leukemia patients and correlated our data with established prognostic markers (for example Binet stage, CD38, IGHV gene mutational status and genomic aberrations) and clinical outcome. Results High expression levels of all RNA-based markers, except MCL1, predicted shorter overall survival and time to treatment, with LPL being the most significant. In multivariate analysis including the RNA-based markers, LPL expression was the only independent prognostic marker for overall survival and time to treatment. When studying LPL expression and the established markers, LPL expression retained its independent prognostic strength for overall survival. All of the RNA-based markers, albeit with varying ability, added prognostic information to established markers, with LPL expression giving the most significant results. Notably, high LPL expression predicted a worse outcome in good-prognosis subgroups, such as patients with mutated IGHV genes, Binet stage A, CD38 negativity or favorable cytogenetics. In particular, the combination of LPL expression and CD38 could further stratify Binet stage A patients. Conclusions LPL expression is the strongest RNA-based prognostic marker in chronic lymphocytic leukemia that could potentially be applied to predict outcome in the clinical setting, particularly in the large group of patients with favorable prognosis.
format	Article
author	Bin Kaderi, Mohd Arifin
author_facet	Bin Kaderi, Mohd Arifin
author_sort	Bin Kaderi, Mohd Arifin
title	LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
title_short	LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
title_full	LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
title_fullStr	LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
title_full_unstemmed	LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
title_sort	lpl is the strongest prognostic factor in a comparative analysis of rna-based markers in early chronic lymphocytic leukemia
publisher	Ferrata Storti Foundation
publishDate	2011
url	http://irep.iium.edu.my/4365/ http://irep.iium.edu.my/4365/ http://irep.iium.edu.my/4365/ http://irep.iium.edu.my/4365/1/RNA_marker_paper.pdf
first_indexed	2018-09-07T03:10:44Z
last_indexed	2018-09-07T03:10:44Z
_version_	1610916660464582656

LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia

Similar Items